IXCHIQ chikungunya vaccine (live attenuated) Updated Nov 15
IXCHIQ's commercial future hinges on whether Valneva can rebuild regulatory trust after the US and UK withdrawals. The positive five-year durability data (94% seroresponse) supports the vaccine's efficacy case, but safety concerns remain the dominant overhang. Valneva reports nine-month 2026 results on November 24, which will provide the clearest read on IXCHIQ's ongoing revenue contribution from EU, Canada and Brazil markets.
- First-to-market advantage: IXCHIQ was the first FDA-approved chikungunya vaccine and remains approved in the EU, Canada, Brazil and other markets.
- Durable efficacy: Five-year follow-up data (November 2026) showed 94% of recipients maintained neutralizing antibody titers above the seroresponse threshold after a single dose.
- Comparable protection in elderly: Antibody persistence in adults 65+ was comparable to younger adults, supporting use in the highest-risk age group.
- US market lost: FDA suspended the license in August 2025 after reports of serious adverse events including encephalitis deaths; Valneva voluntarily withdrew the BLA/IND in January 2026.
- UK market revoked: MHRA revoked marketing authorization in October 2026 after a benefit-risk review found risks outweighed benefits for travelers.
- Safety overhang: Serious adverse events consistent with chikungunya-like illness, including hospitalizations and deaths, primarily in older adults with underlying conditions, have damaged the product's reputation.